Trial reportJournal of the American Geriatrics Society2025
Central Nervous System-Active Medications and Risk of Hospital Readmission in Older Multimorbid Adults.
Trial report in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02986425 (OPERAM), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial
Who cites it
1 citing paper in PubMed.
- Central Nervous System-Active Medications and Risk of Hospital Readmission in Older Multimorbid Adults.Journal of the American Geriatrics Society · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPolypharmacy is associated with adverse outcomes, particularly in older multimorbid adults. However, little is known about the negative outcomes associated with multiple central nervous system (CNS)-active medications that are commonly prescribed to these patients.
objectiveTo assess the association between the number of CNS-active medications at discharge and the risk of 1-year all-cause hospital readmission, drug-related hospital readmission (DRA), death, quality of life (QoL) and functional status in older multimorbid adults.
methodsAmong 2008 older multimorbid inpatients with polypharmacy, we assessed the association between the number of CNS-active medications and 1-year all-cause hospital readmission, DRA, and death by Cox proportional hazard models. We further assessed the association of the number of CNS-active medications with QoL (measured with EQ-5D-VAS) and functional status (measured with Barthel Index) using binary and quantile regression models. Analyses were adjusted for age, sex, discharge location, Charlson Comorbidity Index, depression/anxiety, and randomization arm. Additional sensitivity analyses were adjusted for the number of non-CNS active medications, neurological and psychiatric comorbidities, alcohol or tobacco use, education level, and living arrangements.
resultsThe risk of all-cause hospital readmission and DRA increased by 7% with each additional CNS-active medication (multivariable-adjusted hazard ratio (HR) 1.07 (95% confidence interval 1.03 to 1.12) for all-cause hospital readmission and 1.07 (1.01 to 1.14) for DRA). HR for death was 1.14 (1.07 to 1.23) for each additional CNS-active medication. The mean differences in EQ-5D-VAS and Barthel Index after 1 year were -2.13 (-2.82 to -1.44) and -1.6 (-2.16 to -1.04) respectively, per additional CNS-active medication.
conclusionThe presence of CNS-active medications at discharge is associated with a higher risk for 1-year all-cause hospital readmission and DRA in older multimorbid adults with polypharmacy. Additionally, CNS-active medications were associated with lower QoL and functional status. TRAIL REGISTRATION: ClinicalTrials.gov NCT02986425.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.